EP3827434A1 - Method for the prediction of biological test results - Google Patents
Method for the prediction of biological test resultsInfo
- Publication number
- EP3827434A1 EP3827434A1 EP19761919.0A EP19761919A EP3827434A1 EP 3827434 A1 EP3827434 A1 EP 3827434A1 EP 19761919 A EP19761919 A EP 19761919A EP 3827434 A1 EP3827434 A1 EP 3827434A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- biological
- level
- patient
- neural network
- variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000012360 testing method Methods 0.000 title abstract description 11
- 238000013528 artificial neural network Methods 0.000 claims abstract description 14
- 238000012549 training Methods 0.000 claims abstract description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000004166 bioassay Methods 0.000 claims description 7
- 229940109239 creatinine Drugs 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 210000001772 blood platelet Anatomy 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 210000000265 leukocyte Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
Definitions
- the present invention relates to the field of biological analyzes in resuscitation consisting in measuring the quantities of the constituents of biological liquids (blood, urine, etc.) to provide a health professional with information on the one hand to aid in the diagnosis and monitoring of many diseases, and on the other hand to allow the management of diseases.
- the management of patients in the intensive care unit requires repeated blood tests once or several times daily. These assessments have been shown to cause blood spoliations which contribute to the occurrence of anemia in intensive care. This anemia may require blood transfusions, which poses individual problems (consequences of blood transfusion) and collective problems (resource in blood products). In addition, these repeated biological assessments are expensive.
- the plasma ionogram, blood count, prothrombin time measurement (PT) are the most often performed biological examinations. They are generally performed several times a day in a patient hospitalized in intensive care.
- the invention relates more particularly to the use of artificial intelligence to predict the value of certain biological parameters and thus to reduce the number of blood samples.
- test output in response to receipt of the test output from the trained machine learning software, post-processing the test output to determine if the knowledge discovered from the preprocessed test data set is desirable.
- the aforementioned solution is suitable for highlighting abnormal physiological states.
- each training data point comprises a vector having one or more coordinates.
- Preprocessing the training data set may include identifying missing or erroneous data points and taking appropriate action to correct the faulty data or, if applicable, delete the observation or the whole field from the scope of the problem.
- This solution does not make it possible to predict the “raw” data of a blood test from previous data, then allowing a healthcare professional to draw lessons based on his experience, to possibly decide to have a real sample taken to supplement the predicted data.
- the present invention relates to a method for predicting biological balance sheets of a patient, characterized in that it comprises:
- a learning database consisting in recording a plurality of results of biological assessments B ⁇ carried out on a plurality of resuscitation patients, in the form of a table T comprising a plurality of entries [ VS, VA, VBl-7 ⁇ ] where:
- VA designates a second variable corresponding to the age of the sample
- variable K designates the result of the biological assessment i for the variable K.
- the variable K can be: the potassium level (serum potassium), the sodium level (natremia), the chlorine level (chloremia), the creatinine level ( creatinine), the urea level (uremia), the number of red blood cells, the number of leukocytes, the number of platelets and the protein level (protidemia).
- VBKj being the prediction of the result of the biological balance sheet j for the variable K
- ICKj being the confidence index of VBKj.
- Said neural networks form an antagonistic generative neural network.
- VA, VBK ⁇ ] as well as the value sequences [VBK j ] are time-stamped.
- FIG. 3 represents a timing diagram corresponding to the process illustrated in FIG. 2.
- GANs Geneative Adversarial Networks
- the antagonistic neural networks belong to the class of unsupervised algorithms, and are very efficient when the data to be exploited are important.
- the invention relates to the implementation of these algorithms for predicting the results of a certain proportion of biological examinations in resuscitation patients, as a function of the results of previous biological examinations of the patient. patient, patient's sex, patient's age and learning about the usual evolution of biological examinations as a function of time.
- the invention comprises several stages:
- GRU Gated Recurrent Unit
- This algorithm takes as input nine biological values on admission (Potassium, Sodium, Chlorine, Creatinine, Urea, Red blood cells, Leukocytes, Platelets and Protidemia), as well as the patient's sex and age.
- the technique consists in opposing a fictitious data generator and a discriminator which establishes whether the data is real or fictitious. The generator and the discriminator train each other until the generator generates data that the discriminator can no longer identify as being real or simulated.
- Each biological balance simulation is associated with a confidence indicator for each biological value.
- the algorithm aims to predict the following biological balance and to classify each predicted value as "normal”, “low” or “high”, according to laboratory standards.
- Figure 1 shows a schematic view of
- the input data are recorded in databases (1, 2), in the form of digital sequences obtained from blood samples and the results of their biological analyzes, from a large number of intensive care patients. This is for example historical data from a biological laboratory.
- a sequence is determined comprising the patient's age, patient's sex, date and time of the sample, an anonymized patient identifier and the biological values obtained by analysis of the sample, in the form of a value. numeric corresponding for example to the rate or the count of the biological parameters analyzed.
- the healthcare professional has some analyzes (8) carried out on samples from a patient. These analyzes are carried out on samples at different time-stamped times, and may relate only to part of the biological parameters. To establish new analyzes at a later time, these data (8) are injected into the model (7) which delivers information in the form of estimated values (9) of the biological parameters, each associated with a confidence indicator.
- the healthcare professional can thus assess the situation based on these estimated values (9), and only take a new blood sample if the level of confidence associated with a sensitive biological parameter for his decision is insufficient.
- FIG. 2 illustrates the process of constitution of the data from samples B x carried out on patients P y , resulting in the recording of an incomplete digital table (10) of measured values. Processing determines the missing data (11) requiring processing to estimate the values from the data recorded for a cohort of patients P ⁇ . The next step consists in calculating the missing data by a neuron network (12) generating estimated data validated by a discriminator (13).
- the result is a complete table (14) providing a set of data, without the need for additional sampling.
- FIG. 3 illustrates the timing diagram of the samples, and the fact (lower arrow) that the invention makes it possible to provide all the elements necessary for medical practice by restricting the number of samples from a patient in intensive care.
Landscapes
- Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Bioethics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1856892A FR3084508B1 (en) | 2018-07-25 | 2018-07-25 | METHOD FOR PREDICTING A BIOLOGICAL ASSESSMENT |
PCT/FR2019/051845 WO2020021206A1 (en) | 2018-07-25 | 2019-07-25 | Method for the prediction of biological test results |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3827434A1 true EP3827434A1 (en) | 2021-06-02 |
Family
ID=65763511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19761919.0A Pending EP3827434A1 (en) | 2018-07-25 | 2019-07-25 | Method for the prediction of biological test results |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3827434A1 (en) |
FR (1) | FR3084508B1 (en) |
WO (1) | WO2020021206A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112232549A (en) * | 2020-09-21 | 2021-01-15 | 中国农业科学院农业信息研究所 | Intelligent agricultural product data prediction method and system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6789069B1 (en) | 1998-05-01 | 2004-09-07 | Biowulf Technologies Llc | Method for enhancing knowledge discovered from biological data using a learning machine |
-
2018
- 2018-07-25 FR FR1856892A patent/FR3084508B1/en active Active
-
2019
- 2019-07-25 WO PCT/FR2019/051845 patent/WO2020021206A1/en active Application Filing
- 2019-07-25 EP EP19761919.0A patent/EP3827434A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3084508A1 (en) | 2020-01-31 |
FR3084508B1 (en) | 2023-04-14 |
WO2020021206A1 (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6931897B2 (en) | A method for generating a prediction result for predicting the occurrence of a fatal symptom of a subject at an early stage, and a device using the prediction result. | |
WO2017041651A1 (en) | User data classification method and device | |
CN113053535B (en) | Medical information prediction system and medical information prediction method | |
JP2023016928A (en) | Automated verification of medical data | |
US10327709B2 (en) | System and methods to predict serum lactate level | |
CN112786203A (en) | Machine learning diabetic retinopathy morbidity risk prediction method and application | |
CN114360728A (en) | Prediction model for mild cognitive dysfunction of diabetes and construction method of nomogram | |
Reddy et al. | A Comprehensive analysis of machine learning techniques for incessant prediction of Diabetes mellitus | |
Nimmagadda et al. | Kidney failure detection and predictive analytics for CKD using machine learning procedures | |
WO2020021206A1 (en) | Method for the prediction of biological test results | |
Shapiro | Guidelines for developing and testing clinical decision rules | |
Jones et al. | A framework for the joint modeling of longitudinal diagnostic outcome data and latent infection status: Application to investigating the temporal relationship between infection and disease | |
JP2023545704A (en) | Systems and methods for exposome clinical applications | |
US10325067B1 (en) | Statistical quality control of medical laboratory results | |
Chovancova et al. | Quantitative metabolomics analysis of depression based on PLS-DA model | |
Getmantsev et al. | A novel health risk model based on intraday physical activity time series collected by smartphones | |
KR20210152047A (en) | Apparatus for predicting acute kidney injury using machine learning based on artificial intelligence and method thereof | |
Yördan et al. | Hybrid AI-Based Chronic Kidney Disease Risk Prediction | |
Akter et al. | CKD. Net: A novel deep learning hybrid model for effective, real-time, automated screening tool towards prediction of multi stages of CKD along with eGFR and creatinine | |
Shanmugarajeshwari et al. | Intelligent Decision Support for Identifying Chronic Kidney Disease Stages: Machine Learning Algorithms | |
Garcia-Rios et al. | Predictive machine learning applying cross industry standard process for data mining for the diagnosis of diabetes mellitus type 2 | |
D’Silva et al. | Prediction of Hypertension using Machine Learning | |
Deepa et al. | Experimental evaluation of artificial intelligence assisted heart disease prediction using deep learning principle | |
US10971267B2 (en) | Systems and methods for aggregation of automatically generated laboratory test results | |
Costa et al. | Classification of patients with diabetes by analyzing the patterns of proteins present in saliva using machine learning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240216 |